|
|
|
|
|||||
|
|
|
Emergent BioSolutions Inc. (NYSE:EBS) is one of the Best Performing Affordable Stocks Under $40. On January 8, Emergent BioSolutions Inc. (NYSE:EBS) announced receiving an order worth up to $21.5 million from the US Department of War.
Management noted that the order entails the supply of BioThrax, which is the company’s primary product for anthrax protection, primarily for military personnel at high risk of exposure. Deliveries are expected to occur throughout 2026 with a one-year base period and optional extensions into 2027 and 2028. Management also highlighted that BioThrax remains the only FDA-approved anthrax vaccine, and the latest order aligns with the company’s ongoing role in providing vaccines for US defense needs against biological threats.
That said, on the same day, Emergent BioSolutions Inc. (NYSE:EBS) announced its collaboration with PANTHER to fund the ongoing “MpOx Study in Africa, which is an Africa CDC-led trial testing potential treatments for Mpox. Safety data from the first 50 randomized patients were collected in December, and the trial was cleared to proceed without any issues. Management noted that this partnership positions the company in a high-demand area of Mpox preparedness amid ongoing outbreaks.
Emergent BioSolutions Inc. (NYSE:EBS) is a prominent life sciences company focused on providing solutions to public health threats, including opioid overdoses, infectious diseases, and biological threats.
While we acknowledge the potential of EBS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 7 hours | |
| 10 hours | |
| 12 hours | |
| Jan-15 |
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading
EBS
The Wall Street Journal
|
| Jan-14 | |
| Jan-12 | |
| Jan-08 | |
| Jan-08 | |
| Jan-07 | |
| Dec-12 | |
| Dec-04 | |
| Nov-18 | |
| Nov-12 | |
| Nov-12 | |
| Nov-07 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite